Amgen Presents Open-Label Extension Data From Ongoing Phase 2 Study Of AMG 334 In The Prevention Of Episodic Migraine Jun 19, 2015 04:00PM
Results From Phase 3 Trial Show Vectibix® (Panitumumab) Improves Overall Survival In Chemorefractory Wild-Type KRAS Metastatic Colorectal Cancer Versus Best Supportive Care Jun 18, 2015 04:01PM
Amgen To Discuss Details Of Repatha™ (Evolocumab) Biologics License Application For The Treatment Of High Cholesterol Jun 10, 2015 08:00AM
Amgen To Present At The Goldman Sachs Global Healthcare Conference Jun 8, 2015 04:00PM
Amgen Completes Enrollment In Large Cardiovascular Outcomes Trial Of Repatha™ (Evolocumab) In Patients With High Cholesterol And Clinically Evident Cardiovascular Disease Jun 5, 2015 08:00AM


Jun 2, 2015 01:00AM Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab
Jun 1, 2015 09:00AM Amgen Presents Phase 3 Data At ASCO Showing Prolia® (Denosumab) Significantly Reduced Bone Fractures In Breast Cancer Patients Receiving Aromatase Inhibitors
May 31, 2015 07:00AM Amgen Initiates Phase 3 Study Evaluating Once-Weekly Kyprolis® (carfilzomib) in Patients With Relapsed And Refractory Multiple Myeloma
May 29, 2015 08:30AM Amgen And Merck Announce Expansion Of Collaboration To Support Studies Of Talimogene Laherparepvec In Combination With KEYTRUDA® (Pembrolizumab) In Patients With Head And Neck Cancer
May 29, 2015 06:45AM Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease
May 28, 2015 04:00PM Amgen Launches Program To Further Advance Basic Biology Research
May 27, 2015 04:30PM Amgen To Present At The Jefferies 2015 Global Healthcare Conference
May 27, 2015 04:00PM Amgen To Advance Understanding Of The Treatment Of Blood Cancers At 20th Congress of European Hematology Association (EHA)
May 26, 2015 04:14PM Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma
May 22, 2015 04:22PM Amgen to terminate participation in co-development and commercialization of brodalumab
May 22, 2015 07:31AM Amgen Receives Positive CHMP Opinion For Use Of Repatha™ (Evolocumab) For The Treatment Of High Cholesterol
May 18, 2015 04:00PM Amgen Appoints Jonathan P. Graham Senior Vice President, General Counsel And Secretary
May 15, 2015 04:00AM Amgen Presents First Phase 2 Data For AMG 334 In The Prevention Of Episodic Migraine
May 14, 2015 05:58PM Amgen Announces Voting Results of Annual Meeting of Stockholders
May 13, 2015 05:00PM Amgen Data At ASCO 2015 Highlight Oncology Pipeline And Portfolio
May 12, 2015 04:06PM Amgen's Breakaway From Cancer® Announces Winners Of Its Nationwide Search For Champions In The Fight Against Cancer
May 11, 2015 04:05PM Amgen To Present AMG 334 Data At 17th Congress of the International Headache Society
May 4, 2015 04:17PM Amgen To Present At The Deutsche Bank 40th Annual Healthcare Conference
Apr 29, 2015 09:15AM Amgen Announces FDA Advisory Committee Meeting To Review Repatha™ (Evolocumab) As A Treatment For High Cholesterol
Apr 29, 2015 08:00AM Amgen To Discuss Details Of The Biologics License Application For Talimogene Laherparepvec For Patients With Metastatic Melanoma
Apr 21, 2015 04:01PM Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48
Apr 21, 2015 02:02PM BeyondTrust Appoints Former Northrop Grumman Chairman and CEO Dr. Ronald D. Sugar to Board of Directors
Apr 16, 2015 04:05PM Amgen Announces Webcast Of 2015 First Quarter Financial Results
Apr 15, 2015 05:04PM FDA Approves Corlanor® (ivabradine) To Reduce The Risk Of Hospitalization For Worsening Heart Failure In Patients With Chronic Heart Failure
Apr 6, 2015 05:00AM European Commission Approves Amgen's Vectibix® (panitumumab) As First-Line Treatment In Combination With FOLFIRI Chemotherapy For Metastatic Colorectal Cancer
Mar 30, 2015 04:07PM Amgen To Present At The Goldman Sachs Key Debates In Biosimilars Conference
Mar 30, 2015 09:00AM FDA Grants Amgen Priority Review for Kyprolis® (Carfilzomib) Supplemental New Drug Application for the Treatment of Relapsed Multiple Myeloma
Mar 26, 2015 04:01PM Cancer Survivor Joan Lunden Named 2015 Honorary Breakaway From Cancer® Champion And Joins Nationwide Search For Ten Champions In The Fight Against Cancer
Mar 23, 2015 09:00AM Amgen To Webcast Investor Call At the 73rd Annual Meeting of the American Academy of Dermatology
Mar 20, 2015 09:00AM Amgen Submits Application For Investigational LDL Cholesterol-Lowering Medication Repatha™ (evolocumab) In Japan
Mar 17, 2015 04:01PM Amgen To Present 10 Abstracts From Its Dermatology Portfolio At The 73rd Annual Meeting Of The American Academy Of Dermatology
Mar 15, 2015 11:00AM Amgen Publishes Safety Analysis Of Investigational Cholesterol-Lowering Medication Repatha™ (evolocumab) In The New England Journal of Medicine
Mar 14, 2015 12:30PM New Detailed Data From Phase 3 Study Show Amgen's Repatha™ (Evolocumab) In Combination With Statins Reduced LDL-C By 67-76 Percent Compared To Placebo In Japanese Patients With High Cardiovascular R
Oct 28, 2014 09:33AM Pre-Open Stock Movers 10/28: (RCPT) (TRNX) (VDSI) (MSG) Higher; (TWTR) (AMKR) (CVLT) Lower (more...)
Oct 27, 2014 06:22PM After-Hours Stock Movers 10/27: (TRNX) (RCPT) (SANM) Higher; (AKMR) (TWTR) (KSS) Lower (more...)
Oct 14, 2014 10:03AM UPDATE: Gilead Sciences (GILD) Hits Session Lows
Jul 30, 2014 10:29AM Top 10 Trending Stocks for 07/30: Twitter (TWTR), Amgen (AMGN), Regeneron (REGN), and More...
Jul 30, 2014 09:32AM Pre-Open Stock Movers 7/30: (GFIG) (TWTR) (NQ) Higher; (NTRI) (BWLD) (DWA) Lower (more...)
Jul 29, 2014 06:10PM After-Hours Stock Movers 7/29: (TWTR) (ZLTQ) (X) Higher; (NTRI) (BWLD) (DWA) Lower (more...)
Jul 29, 2014 05:37PM Market Wrap: Home Prices Gain at Slower Pace; Twitter Soars in Q2; Ford Opts for Apple
Jul 28, 2014 05:11PM Trading Radar for 07/29: Pfizer (PFE), Marriott (MAR), UPS (UPS), Anadarko (APC), Ballard Power (BLDP) Report